- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04931017
Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer
Metformin for Chemoprevention of Lung Cancer in High-Risk Overweight or Obese Individuals
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVE:
I. To evaluate the effect of metformin treatment on the expression of programmed cell death protein 1 (PD-1) on airway regulatory T cells (Tregs) in overweight and obese individuals at high risk for lung cancer.
SECONDARY OBJECTIVES:
I. Estimated PD-1 expression of pulmonary Tregs change in Cohort B during the wait period (26 weeks with no treatment).
II. To examine the impact of metformin on circulating immune cell subsets of blood.
EXPLORATORY OBJECTIVES:
I. To examine the impact of metformin on cancer-related transcriptome features of airway lesions.
II. To examine the impact of metformin on immune profile of pulmonary parenchyma represented by bronchoalveolar lavage (BAL).
III To examine the impact of metformin on histologic progression of abnormal airway lesions.
IV. To examine the impact of metformin on serum adipokines and inflammatory cytokines.
OUTLINE: Participants are randomized to 1 of 2 cohorts.
COHORT A: Participants receive metformin extended release (ER) orally (PO) once daily (QD) for 26 weeks in the absence of unacceptable toxicity. Participants undergo bronchoscopy biopsy and blood sample collection at screening, and week 13.
COHORT B: Participants receive no intervention for 26 weeks, then cross-over to cohort A. Participants undergo bronchoscopy biopsy and blood sample collection at screening, at week 26, and at 13 weeks after cross-over to Cohort A.
After completion of study treatment, participants are followed up at weeks 30-32 (Cohort A) and weeks 56-58 (Cohort B).
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6T 2B5
- Not yet recruiting
- University of British Columbia Hospital
-
Contact:
- Stephen Lam
- Phone Number: 604-675-8090
- Email: slam2@bccancer.bc.ca
-
Principal Investigator:
- Stephen Lam
-
Vancouver, British Columbia, Canada, V5Z 1L3
- Recruiting
- BC Cancer Research Centre
-
Contact:
- Stephen Lam
- Phone Number: 604-675-8090
- Email: slam2@bccancer.bc.ca
-
Principal Investigator:
- Stephen Lam
-
-
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- Rocky Mountain Regional VA Medical Center
-
Contact:
- Robert L. Keith
- Phone Number: 720-857-5120
- Email: Robert.keith@cuanschutz.edu
-
Principal Investigator:
- Robert L. Keith
-
-
New York
-
Buffalo, New York, United States, 14263
- Recruiting
- Roswell Park Cancer Institute
-
Contact:
- Saikrishna S. Yendamuri
- Phone Number: 716-364-4852
- Email: sai.yendamuri@roswellpark.org
-
Principal Investigator:
- Saikrishna S. Yendamuri
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Former smokers (male and female) with a >= 20 pack year smoking history
- Quit smoking >= 12 months prior to enrollment
- Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCOm2012) Lung Cancer Risk Prediction Score > 1.34%
Overweight
- Body mass index (BMI) > 25 and
Waist circumference
- Female > 88 cm (35")
- Male > 102 cm (40")
- Age greater than 30 years. Participants younger than 30 years are unlikely to accrue enough smoking exposure followed by enough time after quitting (>12 months) to qualify
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2
- Leukocytes >= 3,000/microliter
- Absolute neutrophil count (ANC) >= 1,000/microliter
- Platelets >= 100,000/microliter
- Total bilirubin =< 1.5 x institutional upper limit of normal (IULN)
- Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3.0 x IULN
- Estimated glomerular filtration rate (eGFR) > 45 ml/min/1.73 m^2 (eGFR will be calculated using the equation Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] creatinine)
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured
- Patients on chronic suppressive antiviral therapy for herpes simplex virus (HSV) are eligible
- The effects of metformin ER on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Current or previous diagnosis of diabetes mellitus (type I or type II diabetes)
- Use of metformin within the past 2 years
- Use of GLP-1 agonists within 6 weeks prior to enrollment
- Glycosylated hemoglobin A1C (HbA1c) > 8%
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin ER
- Participants currently using immunosuppressive medication, including systemic steroids (not inhalational) and episodic use of inhaled steroids are excluded from this trial due to the potential impact of these treatments on the primary trial endpoint
- Participants receiving any other investigational agents
History of chronic alcohol use or abuse defined by any one of the following:
- Average consumption of 3 or more alcohol containing beverages daily in the past 12 months
- Consumption of 7 or more alcoholic beverages within a 24 hour period in the past 12 months
- Acute or chronic liver disease, evidence of hepatitis (infectious or autoimmune), cirrhosis or portal hypertension
- History of or current condition predisposing to increased risk for lactic acidosis such as: severe congestive heart failure (New York Heart Association [NYHA] class III or IV), metabolic acidosis, severe liver disease, or renal failure
- Uncontrolled intercurrent illness or psychiatric illness/social situations that would or limit compliance with study requirements
- Pregnant women are excluded from this study. Metformin ER is a class B agent that was not teratogenic in rats and rabbits at doses representing 3 and 6 times the maximum recommended human daily dose of 2000 mg; however, animal reproduction studies are not always predictive of human response. Because there is an unknown but potential risk for adverse events (AEs) in nursing infants secondary to treatment of the mother with metformin ER, breastfeeding should be discontinued if the mother is treated with metformin ER
Biopsy with invasive carcinoma of the lung or carcinoma in situ
- Participants with prior stage 1 non-small cell lung cancer (NSCLC) diagnosis are allowed to participate, as long as there has been 12 months since the completion of cancer treatment prior to enrollment with no evidence of recurrence or second primary cancer
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort A (metformin ER)
Participants receive metformin ER PO QD for 26 weeks in the absence of unacceptable toxicity.
Participants undergo bronchoscopy biopsy and blood sample collection at screening, and week 13.
|
Ancillary studies
Undergo blood sample collection
Other Names:
Undergo biopsy
Other Names:
Given PO
Other Names:
Undergo bronchoscopy
|
Active Comparator: Cohort B (metformin ER with waiting period)
Participants receive no intervention for 26 weeks, then cross-over to Cohort A. Participants undergo bronchoscopy biopsy and blood sample collection at screening, at week 26, and at 13 weeks after cross-over to Cohort A.
|
Ancillary studies
Undergo blood sample collection
Other Names:
Undergo biopsy
Other Names:
Given PO
Other Names:
Undergo bronchoscopy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PD-1 expression of pulmonary regulatory T cells (Tregs) before and after metformin extended release (ER) treatment
Time Frame: Pre- to post-treatment
|
Change from pre- to post-metformin extended release (ER) treatment in cell surface PD-1 expression levels of pulmonary (BAL) Tregs, measured as mean fluorescent intensity (MFI).
Changes in MFI due to metformin ER treatment among all n = 40 subjects will be used for the primary analysis.
|
Pre- to post-treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Estimated PD-1 expression of pulmonary Tregs change in cohort B during the wait period (6 months with no treatment)
Time Frame: Randomization to week 26
|
This is the estimate of change in MFI following the 6-month wait period among n = 20 subjects randomized to the wait-list arm.
This will confirm the stability of the PD-1 expression of pulmonary Tregs over time.
|
Randomization to week 26
|
Circulating immune cells
Time Frame: Pre- to post-treatment
|
Circulating immune cell composition between blood samples collected pre- and post-metformin ER treatment to assess the effect of metformin ER on circulating immune cells and to identify potential biomarkers of metformin ER response.
|
Pre- to post-treatment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Airway gene expression
Time Frame: Up to study completion
|
RNA sequencing of endobronchial biopsies will be performed at visually normal mainstem airway for each participant.
The analysis of the RNA seq data will be an unsupervised comparison of differentially expressed genes with and without metformin ER exposure.
|
Up to study completion
|
Examination of the immune profile of pulmonary parenchyma represented by bronchoalveolar lavage
Time Frame: Pre- to post-treatment
|
This will compare the immune composition of bronchoalveolar lavage samples of participants before and after metformin exposure.
Specifically, the prevalence and composition of myeloid derived suppressor cells (MDSCs) as well as monocyte, macrophage and dendritic cells will be assessed.
|
Pre- to post-treatment
|
Examination of the effect of metformin on systemic adipokines and inflammatory cytokines
Time Frame: Pre- to post-treatment
|
Frozen sera will be analyzed by commercial enzyme-linked immunosorbent assay kits for levels of leptin, adiponectin, resistin, IL6 and TNFalpha.
Pre- and post-treatment serum levels will be compared in parametric paired testing.
|
Pre- to post-treatment
|
Histologic progression
Time Frame: Up to study completion
|
Bronchoscopic biopsies of at least 6 standard sites will be graded on the World Health Organization (WHO) scale of dysplasia and assigned numerical scores from 1 (normal) to 8 (invasive cancer).
Each lesion will be classified as complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD) and each response rate will be calculated on a per-site and a per-participant basis.
Additional measures of dysplasia will include the average dysplastic score and the dysplasia index (% of sites with dysplasia score >= 3 (mild dysplasia)).
Changes in maximum dysplasia will be analyzed using a paired t test to determine whether a reduction occurs.
|
Up to study completion
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Saikrishna S Yendamuri, Roswell Park University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCI-2021-06112 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- P30CA060553 (U.S. NIH Grant/Contract)
- UG1CA242643 (U.S. NIH Grant/Contract)
- NCI20-04-01 (Other Identifier: Northwestern University)
- NWU20-04-01 (Other Identifier: DCP)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Carcinoma
-
National Cancer Institute (NCI)CompletedLung Adenocarcinoma | Recurrent Non-Small Cell Lung Carcinoma | Adenosquamous Lung Carcinoma | Bronchioloalveolar Carcinoma | Large Cell Lung Carcinoma | Squamous Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedCarcinoma, Non-Small Cell Lung | Carcinoma, Small-Cell LungUnited States
-
Ohio State University Comprehensive Cancer CenterNational Institute on Aging (NIA)CompletedStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Advanced Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell Carcinoma | Unresectable Lung Non-Small Cell Carcinoma | Unresectable Lung CarcinomaUnited States
-
Ohio State University Comprehensive Cancer CenterNational Institute on Aging (NIA)RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell Carcinoma | Unresectable Lung Non-Small Cell Carcinoma | Advanced Lung Non-Small Cell Carcinoma | Advanced... and other conditionsUnited States
-
Pathway GenomicsTerminatedLung Neoplasms | Lung Cancer | Adenocarcinoma of the Lung | Cancer of the Lung | Small Cell Carcinoma of the Lung | Non Small Cell Carcinoma of the LungUnited States
-
National Cancer Institute (NCI)RecruitingExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Recurrent Lung Small Cell CarcinomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Society of Thoracic RadiologyActive, not recruitingStage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
Latin American Cooperative Oncology GroupConselho Nacional de Desenvolvimento Científico e Tecnológico; Instituto do...CompletedNon-small Cell Lung CarcinomaBrazil
-
Spectrum Pharmaceuticals, IncWithdrawnNon-Small-Cell Lung CarcinomaUnited States, Russian Federation
-
Ontario Clinical Oncology Group (OCOG)Ontario Ministry of Health and Long Term CareCompletedPositron Emission Tomography (PET) Imaging in Stage III Non-small Cell Lung Cancer (PET START Trial)Non-Small-Cell Lung CarcinomaCanada
Clinical Trials on Questionnaire Administration
-
Fondazione Don Carlo Gnocchi OnlusUnknown
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
Istanbul Aydın UniversityCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBreast Carcinoma | Fallopian Tube Carcinoma | Endometrial Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma | Deleterious CDH1 Gene Mutation | Deleterious DICER1 Gene Mutation | Deleterious SMARCA4 Gene Mutation | Deleterious STK11 Gene MutationUnited States
-
Hospital Clínico Universitario de ValladolidRed Centinela Sanitaria de Castilla y León (RCSCYL); Centro Nacional de Gripe... and other collaboratorsRecruitingMigraine | Headache Disorders | Viral Infection | Influenza -Like Illness | Head PainSpain
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | COVID-19 Infection | Hereditary Breast CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Plasma Cell Myeloma | Caregiver | Recurrent LeukemiaUnited States
-
I.M. Sechenov First Moscow State Medical UniversityAgency of Social Information St. PetersburgActive, not recruiting
-
I.M. Sechenov First Moscow State Medical UniversityActive, not recruitingShoulder ArthropathyRussian Federation